| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | Form 4 |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing |
| 09 Nov 2026 |
Form 4: ADAR1 Capital Management, Llc, 10% owner and 1 other
Bought 1,024 shares ($5.22K) · Bought 3,662 shares ($18.7K) |
| 06 Nov 2026 | EFFECT |
| 06 Nov 2026 | 424B3 |
| 06 Nov 2026 | S-4/A |
| 02 Nov 2026 | S-4/A |
| 30 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 26, 2026 NextCure, Inc. (the “Company”) determined that the employment of Dr. Udayan Guha, M.D., Ph.D., Chief Medical Officer and a named executive officer of the Company, will be terminated effective October 31, 2026, in cont... |
| 27 Oct 2026 |
Form 4: ADAR1 Capital Management, Llc, 10% owner and 1 other
Bought 5,626 shares ($27.2K) · Bought 1,672 shares ($8.42K) · Bought 3,553 shares ($18.1K) |
| 20 Oct 2026 | SCHEDULE 13G |
| 01 Oct 2026 | S-4/A |
| 25 Sep 2026 | 425 |
| 25 Sep 2026 |
8-K: Other Events
Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a potentially defective corporate act as follows: |
| 03 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
This NINTH AMENDMENT TO LEASE AGREEMENT (“this Ninth Amendment”) is dated as of August 28, 2026 (“Effective Date”), by and between ARE-8000/9000/10000 VIRGINIA MANOR, LLC, a Delaware limited liability company, having an address at 26 Nor... |
| 18 Aug 2026 | S-4 |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
Loading...